Johnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice President of Investor Relations

News provided by

Jun 22, 2016, 06:45 ET

NEW BRUNSWICK, N.J., June 22, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, will retire in January 2017, after a transition period with her successor. Louise first joined the Johnson & Johnson Family of Companies in 1980, and has led Investor Relations for more than 10 years.

"Louise has been a constant advocate for transparency and credibility in our financial communications, a trusted advisor to company management, and her commitment to excellence has led to the development of a best-in-class IR team," said Dominic J. Caruso, Executive Vice President, Chief Financial Officer of Johnson & Johnson. "We sincerely thank her for more than 35 years of service, and for her leadership in helping develop a strong and diverse Finance organization at Johnson & Johnson."

Joseph Wolk will replace Mehrotra as Vice President, Investor Relations, effective August 1. Wolk will continue to report to Dominic Caruso.

"Joe is a proven leader in our Finance organization, and we are confident he will continue our commitment to transparent and credible engagement with the investment community. His cross-sector expertise, prudent financial management and focus on talent development will ensure the investor relations function at Johnson & Johnson remains best-in-class," said Caruso.

Wolk was previously Vice President, Group Finance for the Pharmaceuticals Group of Johnson & Johnson, where he provided finance leadership, supporting Worldwide Chairman, Pharmaceuticals Joaquin Duato, and Chief Scientific Officer Paul Stoffels, as a member of the Pharmaceuticals Group Operating Committee. Prior to that role, he held other finance leadership positions at Johnson & Johnson as Vice President of Finance for the Medical Devices Global Supply Chain, and as Chief Financial Officer of the North America Pharmaceuticals Group, responsible for Centocor Ortho Biotech Inc., as well as U.S. Pricing Strategy and Compliance. Wolk joined Johnson & Johnson in 1998 as a Finance Manager in the Ortho-McNeil Pharmaceutical organization.

Prior to joining Johnson & Johnson, Wolk held multiple positions of increasing responsibility at Ametek, Inc. He holds a Bachelor of Science degree in Finance from St. Joseph's University, where he currently serves on the Haub School of Business Board of Visitors, and he also holds a Juris Doctor degree from Temple University School of Law and is a Certified Public Accountant.

For a complete list of Johnson & Johnson Investor Relations contacts, please visit www.investor.jnj.com.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

SOURCE Johnson & Johnson